Granules India reported strong financial results for Q3 FY26, with revenue reaching INR 1,388 crores, a 22% year-over-year increase. EBITDA grew by 34% to INR 308 crores, driven by disciplined execution and improved operating leverage. Regulatory excellence remains a key priority, with steady progress across all facilities. The company continues to advance digitalization of manual operations across its network to strengthen reliability and resilience.
Financial Highlights for Q3 FY26
Granules India Limited has announced a robust financial performance for the third quarter of FY26. Key highlights include:
- Revenue: Reported at INR 1,388 crores, reflecting a 22% increase compared to Q3 FY25.
- EBITDA: Reached INR 308 crores, a 34% growth over the same period last year.
- Gross Margin: Achieved 63.9%, representing a year-on-year improvement.
Business Segment Performance
The revenue growth was broad-based, with significant contributions from the formulation business in North America and Europe. This reflects the strength of the company’s diversified business model and progress on multiple strategic fronts. The company’s strategic priorities include transitioning to higher complexity generics and strengthening market presence across key geographies.
Regulatory and Quality Updates
Regulatory excellence remains a critical priority for Granules India. The company made steady progress across all its facilities during the quarter. A post-warning letter meeting was held with the FDA in early January regarding the Gagillapur facility. The company will be submitting requested documentation shortly and remains confident about the pathway to resolution. Additionally, the GLS facility at Genome Valley received a US FDA inspection in December, with responses submitted within the stipulated timelines.
R&D and Filings
Granules India’s R&D and regulatory pipeline progressed well during the quarter. This included the filing of 1 EU dossier, 8 new product registrations in rest of the world markets, and 4 DMFs in rest of the world countries. Approvals included a tentative U.S. FDA approval for generic Adzenys from GPI and 1 DMF approval in China. The company’s increasing focus on ROW markets supports its strategy to diversify beyond the US and Europe.
Ascelis Peptides Update
Performance in Q3 was modest but consistent with the transition phase. Q3 was focused on executing key projects, increasing utilization, and strengthening delivery readiness for Q4. INR33 crores in revenue this quarter. Deliveries are expected to increase significantly in Q4.
ESG Progress
Sustainability continues to be a core part of Granules India. This quarter, the company’s CDP climate change rating improved to A up from B. The S&P CSA score increased to 62, placing it among the top 10% of global peers. The Gagillapur facility achieved zero waste to landfill, with over 99% waste diversion.
Source: BSE
